Sonoma Pharmaceuticals (NASDAQ: SNOA) updates investor presentation

Rhea-AI Filing Summary

Sonoma Pharmaceuticals, Inc. filed a Form 8-K to provide investors with an updated company investor presentation, which is included as Exhibit 99.1 and dated September 29, 2025. The presentation is intended to give an overview of the company’s business, commercial activities, technology progress, and expectations for future financial performance.

The filing emphasizes that these expectations are forward-looking statements and may differ from actual results due to a range of risks. These include potential changes in regulatory or clinical guidelines, the possibility that scientific or clinical data may not meet regulatory standards or be replicated in real-world use, challenges to the company’s patents, smaller-than-expected market opportunities, limited product penetration, and revenue levels that may not meet cash needs. Additional risks mentioned relate to foreign currency fluctuations, global economic conditions, trade policy changes, and varying regulatory and marketing requirements in different regions.

false 0001367083 0001367083 2025-09-29 2025-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 29, 2025

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-33216		68-0423298
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

5445 Conestoga Court, Suite 150

Boulder, CO 80301

(Address of principal executive offices)

(Zip Code)

(800) 759-9305

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock	SNOA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1.

Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company.

These forward-looking statements are identified by the use of words such as “will,” “develop,” “project,” “expect,” and “expand,” among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Investor Presentation as of September 29, 2025.
104		Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).

___________________

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SONOMA PHARMACEUTICALS, INC.
Date: September 29, 2025	By:	/s/ Amy Trombly
	Name: Title:	Amy Trombly Chief Executive Officer

2

FAQ

What did Sonoma Pharmaceuticals (SNOA) report in this Form 8-K?

Sonoma Pharmaceuticals reported that it has prepared an updated investor presentation. This presentation, attached as Exhibit 99.1, provides information about the company’s business, commercial activities, technology progress, and expectations for future financial performance.

What is included in Exhibit 99.1 for Sonoma Pharmaceuticals (SNOA)?

Exhibit 99.1 is an updated investor presentation of Sonoma Pharmaceuticals as of September 29, 2025. It is intended to give investors an overview of the company, its products and technology, and its outlook for future financial performance.

Does Sonoma Pharmaceuticals discuss future performance in this filing?

Yes. The company notes that the investor presentation includes forward-looking statements about commercial and technology progress and future financial performance. These statements are described as being made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

What risks and uncertainties does Sonoma Pharmaceuticals highlight around its outlook?

The company states that results could differ from its forward-looking statements due to risks such as regulatory and guideline changes, scientific or clinical data not meeting regulatory standards, clinical results not being replicated in patient settings, challenges to its patents, smaller-than-expected market sizes, limited product penetration, and revenues that may not meet cash needs. It also cites risks related to foreign currency fluctuations, global economic conditions, trade policy changes, and differing regulatory and marketing requirements across jurisdictions.

Does Sonoma Pharmaceuticals commit to updating its forward-looking statements?

No. The company specifically notes that it disclaims any obligation to update its forward-looking statements, except as required by law.

Who signed the Sonoma Pharmaceuticals Form 8-K for this investor presentation update?

The Form 8-K was signed on behalf of Sonoma Pharmaceuticals, Inc. by Amy Trombly, who is identified as the company’s Chief Executive Officer.